Status | Study |
Recruiting |
Study Name: South Australian Meningococcal B Vaccine Herd Immunity Study Condition: Meningococcal Disease Date: 2017-03-17 Interventions: Biological: Licensed 4CMenB vaccine Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month t |
Recruiting |
Study Name: Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination Condition: Infections, Meningococcal Date: 2016-12-06 Interventions: Biological: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo) |
Recruiting |
Study Name: Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents Condition: Infections, Meningococcal Date: 2016-10-25 Interventions: Biological: Meningococcal ABCWY Vaccine |
Recruiting |
Study Name: PRIME Follow up - Quadri Meningo Vacinees Condition: Meningococcal Disease Date: 2016-06-15 Interventions: Other: venepuncture only single venepuncture |
Active, not recruiting |
Study Name: Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization Condition: Meningococcal Infections Date: 2016-03-14 Interventions: Biological: 4CMenb Other Name: |
Active, not recruiting |
Study Name: Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Condition: Meningococcal Disease Date: 2015-12-21 Interventions: Biological: MenC-CRM conjugate vaccine with 12.5 ug LHD153R |
Active, not recruiting |
Study Name: Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Condition: Meningococcal Infections Date: 2015-09-30 Interventions: Biological: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals) All subjects will receive three doses of a T |
Completed |
Study Name: A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years Condition: MENINGOCOCCAL INFECTION Date: 2015-08-20 Interventions: Biological: Bivalent rLP2086 Vaccine |
Active, not recruiting |
Study Name: Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations Condition: Meningococcal Disease Date: 2015-05-13 Interventions: Biological: Menveo® Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age fol |
Completed |
Study Name: Combined Study - Phase 3b MenB Long Term Persistence in Adolescents Condition: Infections, Meningococcal Date: 2015-05-06 Interventions: Biological: Meningococcal Group B (rDNA Component adsorbed) (rMenB+OMV NZ) In Group A, intramuscular Boo |